MetLife Investment Management’s Enliven Therapeutics ELVN Stock Holding History

MetLife Investment Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$866K	Sell	22,094 -2,462	-10%	-$68.2K	﹤0.01%	1471
2025 Q4	$378K	Hold	24,556	–	–	﹤0.01%	1926
2025 Q3	$503K	Buy	24,556 +3,345	+16%	+$67.4K	﹤0.01%	1800
2025 Q2	$425K	Sell	21,211 -258	-1%	-$4.88K	﹤0.01%	1760
2025 Q1	$423K	Sell	21,469 -277	-1%	-$5.96K	﹤0.01%	1808
2024 Q4	$489K	Buy	21,746 +1,285	+6%	+$33.3K	﹤0.01%	1816
2024 Q3	$523K	Hold	20,461	–	–	﹤0.01%	1761
2024 Q2	$478K	Buy	20,461 +8,116	+66%	+$171K	﹤0.01%	1737
2024 Q1	$217K	Hold	12,345	–	–	﹤0.01%	2162
2023 Q4	$171K	Hold	12,345	–	–	﹤0.01%	2327
2023 Q3	$169K	Hold	12,345	–	–	﹤0.01%	2302
2023 Q2	$252K	Buy	+12,345	New	+$249K	﹤0.01%	2134

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MetLife Investment Management's ELVN Position: Q1 2026 in Review

MetLife Investment Management reduced its Enliven Therapeutics (ELVN) stake by 10% in Q1 2026, selling an estimated $68.2K and leaving 22,094 shares worth $866K. The position accounts for ﹤0.01% of the portfolio, ranked #1471.

MetLife Investment Management first reported a position in ELVN in Q2 2023 and has held it in 12 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

MetLife Investment Management held 22,094 shares of Enliven Therapeutics worth $866K as of Q1 2026.
MetLife Investment Management sold 2,462 Enliven Therapeutics shares in Q1 2026, an estimated $68.2K.
Enliven Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1471 holding.
MetLife Investment Management first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 12 quarters since.
170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.